No sooner does one gammadelta-focused biotech die than another takes its place.
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
The company might have blown Enliven out of the water.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
Pfizer reveals the discontinuation of PF-08046044.
